Brief announcement: passive and active attacks on audience response systems using software defined radios

Audience response systems, also known as clickers, are used at many academic institutions to offer active learning environments. Since these systems are used to administer graded assignments, and sometimes even exams, it is crucial to assess their security. Our work seeks to exploit and document potential vulnerabilities of clickers. For this purpose, we use software defined radios to perform jamming, sniffing and spoofing attacks on an audience response system in production, which provide different possible methods of cheating. The results of our study demonstrate that clickers are easily exploitable. We build a prototype and show that it is practically possible to covertly steal or forge answers of a peer or even an entire classroom, with high levels of confidence. Additionally, we find that the receivers software of the system lacks protection against unexpected answers, which allows our spoofer to submit any ASCII character and opens the receiver up to possible fuzzing attacks. As a result of this study, we discourage using clickers for high-stake assessments, unless they provide proper security protection..http://people.bu.edu/staro/SSS2017_Brief_v0.pdfhttp://people.bu.edu/staro/SSS2017_Brief_v0.pdfhttp://people.bu.edu/staro/SSS2017_Brief_v0.pdfAccepted manuscrip

Posterior sub-Tenon capsule anesthesia for photocoagulation treatment of diabetic retinopathy performed in an inner-city county hospital clinic setting

poster abstractProliferative diabetic retinopathy (PDR) is a blinding eye disease demanding prompt therapy. However, treatment with panretinal photocoagulation (PRP) can be painful thereby limiting its extent. In addition, compliance to diabetic eye visits remains poor particularly in inner cities. Therefore, it is imperative to optimize treatment during clinic visits. The purpose of this study is to present the effect of sub-Tenon (Sub-T) capsule lidocaine anesthesia on PRP treatment extent for PDR performed during the eye clinic visit. This is an IRB-approved retrospective review of initial 12 eyes (9 subjects) with PDR undergoing PRP treatment involving Sub-T anesthesia in the eye clinic. Sub-T capsule lidocaine anesthesia was delivered and PRP was immediately performed. Primary end point was extent of treatment (number of PRP laser spots) delivered. Comparison was made to PRP in prior sessions without Sub-T anesthesia. All subjects had active PDR and sometimes vitreous hemorrhage (VH) at time of treatment. Decision was made to offer Sub-T anesthesia due to intolerable pain from prior PRP treatments in all subjects. We observed all subjects were able to tolerate a significantly greater extent of PRP with Sub-T anesthesia even with presence of VH, oftentimes undergoing thousands of laser spots and capable to complete treatment in same clinic visit. By comparison, prior PRP treatments (without Sub-T anesthesia) were much less extensive sometimes involving only a few laser spots. We conclude that Sub-T anesthesia allows a tier of pain control for those not able to tolerate traditional PRP without anesthesia performed in the eye clinic. This new information suggests that certain patients undergoing PRP can be offered Sub-T anesthesia, and it will be important to define algorithm for selection of such individuals

Myelodysplastic/Myeloproliferative Neoplasms

Myeloid malignancies exemplified by acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs) are all characterized by abnormal proliferation of stem cells. AML is characterized by proliferation of myeloid blasts that ultimately perturb normal bone marrow (BM) function and suppress hematopoiesis. The hallmarks of MDS are cytopenias (anemia, leukopenia, or thrombocytopenia), impaired differentiation in one or more of myeloid cell lines, and ineffective hematopoiesis (Tiu et al. 2011a). MPNs manifest with proliferation of one or more cell lines in the BM with accompanying BM fibrosis and extramedullary hematopoiesis (Fig. 1). When features of both MDS and MPN coexist in the same patient, the disease is called MDS/MPN overlap neoplasms. The recognition that some MDS patients have overlapping MPN features led to the coining of the term MDS/MPN overlap. This group was first described in 1997 at the clinical advisory meeting of the World Health Organization (WHO) (Harris et al. 1999) and later adapted in the 2001 WHO classification (Harris et al. 2001). As in the case of MDS and MPNs, MDS/MPN patients are also at risk for AML evolution. Within this overlapping class, four different disease entities were classified: Juvenile myelomonocytic leukemia (JMML), chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (BCR-ABL1 negative) (aCML), and MDS/MPN-unclassifiable (MDS/MPN-U), which also included the provisional disease category, refractory anemia with ring sideroblast associated with marked thrombocytosis (RARS-T). Of note, each of these disease entities has a defined natural history, influenced by a variety of factors such as BM blast counts, presence of concomitant diseases (e.g., systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease [SM-AHNMD]), and different cytogenetic and epigenetic/molecular profile which may explain the clinicopathologic diversity of these diseases

Practical Flapping Mechanisms for 20cm-span Micro Air Vehicles

[[abstract]]In the body of research relevant to high-performance flapping micro air vehicles (MAV), development of light-weight, compact and energy-efficient flapping mechanisms occupies a position of primacy due to its direct impact on the flight performance and mission capability. Realization of such versatile flapping mechanism with additional ability of producing thrust levels that fulfill requirements of cruising forward flight and vertical take-off and landing (VTOL) conditions demand extensive design validation and performance evaluation. This paper presents a concerted approach for mechanism development of a 20 cm span flapping MAV through an iterative design process and synergistic fabrication options involving electrical-discharge-wire-cutting (EDWC) and injection molding. Dynamic characterization of each mechanism is done through high speed photography, power take-off measurement, wind tunnel testing and proof-of-concept test flights. The research outcome represents best-in-class mechanism for a 20 cm span flapping MAV with desirable performance features of extra-large flapping stroke up to 100°, minimal transverse vibrations and almost no phase lag between the wings.[[notice]]補正完畢[[journaltype]]國外[[incitationindex]]SCI[[ispeerreviewed]]Y[[booktype]]紙本[[countrycodes]]US

Validation of a deep neural network-based algorithm supporting clinical management of adnexal mass

BackgroundConservative management of adnexal mass is warranted when there is imaging-based and clinical evidence of benign characteristics. Malignancy risk is, however, a concern due to the mortality rate of ovarian cancer. Malignancy occurs in 10–15% of adnexal masses that go to surgery, whereas the rate of malignancy is much lower in masses clinically characterized as benign or indeterminate. Additional diagnostic tests could assist conservative management of these patients. Here we report the clinical validation of OvaWatch, a multivariate index assay, with real-world evidence of performance that supports conservative management of adnexal masses.MethodsOvaWatch utilizes a previously characterized neural network-based algorithm combining serum biomarkers and clinical covariates and was used to examine malignancy risk in prospective and retrospective samples of patients with an adnexal mass. Retrospective data sets were assembled from previous studies using patients who had adnexal mass and were scheduled for surgery. The prospective study was a multi-center trial of women with adnexal mass as identified on clinical examination and indeterminate or asymptomatic by imaging. The performance to detect ovarian malignancy was evaluated at a previously validated score threshold.ResultsIn retrospective, low prevalence (N = 1,453, 1.5% malignancy rate) data from patients that received an independent physician assessment of benign, OvaWatch has a sensitivity of 81.8% [95% confidence interval (CI) 65.1–92.7] for identifying a histologically confirmed malignancy, and a negative predictive value (NPV) of 99.7%. OvaWatch identified 18/22 malignancies missed by physician assessment. A prospective data set had 501 patients where 106 patients with adnexal mass went for surgery. The prevalence was 2% (10 malignancies). The sensitivity of OvaWatch for malignancy was 40% (95% CI: 16.8–68.7%), and the specificity was 87% (95% CI: 83.7–89.7) when patients were included in the analysis who did not go to surgery and were evaluated as benign. The NPV remained 98.6% (95% CI: 97.0–99.4%). An independent analysis set with a high prevalence (45.8%) the NPV value was 87.8% (95% CI: 95% CI: 75.8–94.3%).ConclusionOvaWatch demonstrated high NPV across diverse data sets and promises utility as an effective diagnostic test supporting management of suspected benign or indeterminate mass to safely decrease or delay unnecessary surgeries

Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens.

BackgroundTo determine differentially expressed and spliced RNA transcripts in chronic lymphocytic leukemia specimens a high throughput RNA-sequencing (HTS RNA-seq) analysis was performed.MethodsTen CLL specimens and five normal peripheral blood CD19+ B cells were analyzed by HTS RNA-seq. The library preparation was performed with Illumina TrueSeq RNA kit and analyzed by Illumina HiSeq 2000 sequencing system.ResultsAn average of 48.5 million reads for B cells, and 50.6 million reads for CLL specimens were obtained with 10396 and 10448 assembled transcripts for normal B cells and primary CLL specimens respectively. With the Cuffdiff analysis, 2091 differentially expressed genes (DEG) between B cells and CLL specimens based on FPKM (fragments per kilobase of transcript per million reads and false discovery rate, FDR q < 0.05, fold change >2) were identified. Expression of selected DEGs (n = 32) with up regulated and down regulated expression in CLL from RNA-seq data were also analyzed by qRT-PCR in a test cohort of CLL specimens. Even though there was a variation in fold expression of DEG genes between RNA-seq and qRT-PCR; more than 90 % of analyzed genes were validated by qRT-PCR analysis. Analysis of RNA-seq data for splicing alterations in CLL and B cells was performed by Multivariate Analysis of Transcript Splicing (MATS analysis). Skipped exon was the most frequent splicing alteration in CLL specimens with 128 significant events (P-value <0.05, minimum inclusion level difference >0.1).ConclusionThe RNA-seq analysis of CLL specimens identifies novel DEG and alternatively spliced genes that are potential prognostic markers and therapeutic targets. High level of validation by qRT-PCR for a number of DEG genes supports the accuracy of this analysis. Global comparison of transcriptomes of B cells, IGVH non-mutated CLL (U-CLL) and mutated CLL specimens (M-CLL) with multidimensional scaling analysis was able to segregate CLL and B cell transcriptomes but the M-CLL and U-CLL transcriptomes were indistinguishable. The analysis of HTS RNA-seq data to identify alternative splicing events and other genetic abnormalities specific to CLL is an added advantage of RNA-seq that is not feasible with other genome wide analysis

Infrared Spectroscopic Observations of the Secondary Stars of Short Period Sub-Gap Cataclysmic Variables

We present K-band spectroscopy of short period, "sub-gap" cataclysmic variable (CV) systems obtained using ISAAC on the VLT. We show the infrared spectra (IR) for nine systems below the 2-3 hour period gap: V2051 Oph, V436 Cen, EX Hya, VW Hyi, Z Cha, WX Hyi, V893 Sco, RZ Leo, and TY PsA. We are able to clearly detect the secondary star in all but WX Hyi, V893 Sco, and TY PsA. We present the first direct detection of the secondary stars of V2051 Oph, V436 Cen, and determine new spectral classifications for EX Hya, VW Hyi, Z Cha, and RZ Leo. We find that the CO band strengths of all but Z Cha appear normal for their spectral types, in contrast to their longer period cousins above the period gap. This brings the total number of CVs and pre-CVs with moderate resolution (R >~ 1500) IR spectroscopy to sixty-one systems: nineteen pre-CVs, thirty-one non-magnetic systems, and eleven magnetic or partially magnetic systems. We discuss the trends seen in the IR abundance patterns thus far, and highlight a potential link between anomalous abundances seen in the IR with the C IV/N V anomaly seen in the ultraviolet. We present a compilation of all systems with sufficient resolution IR observations to assess the CO band strengths, and, by proxy, obtain an estimate on the C abundance on the secondary star.Comment: 44 pages, 8 figures, 4 tables. Accepted for publication to Ap

Single hadron response measurement and calorimeter jet energy scale uncertainty with the ATLAS detector at the LHC

The uncertainty on the calorimeter energy response to jets of particles is derived for the ATLAS experiment at the Large Hadron Collider (LHC). First, the calorimeter response to single isolated charged hadrons is measured and compared to the Monte Carlo simulation using proton-proton collisions at centre-of-mass energies of sqrt(s) = 900 GeV and 7 TeV collected during 2009 and 2010. Then, using the decay of K_s and Lambda particles, the calorimeter response to specific types of particles (positively and negatively charged pions, protons, and anti-protons) is measured and compared to the Monte Carlo predictions. Finally, the jet energy scale uncertainty is determined by propagating the response uncertainty for single charged and neutral particles to jets. The response uncertainty is 2-5% for central isolated hadrons and 1-3% for the final calorimeter jet energy scale.Comment: 24 pages plus author list (36 pages total), 23 figures, 1 table, submitted to European Physical Journal

Standalone vertex finding in the ATLAS muon spectrometer

A dedicated reconstruction algorithm to find decay vertices in the ATLAS muon spectrometer is presented. The algorithm searches the region just upstream of or inside the muon spectrometer volume for multi-particle vertices that originate from the decay of particles with long decay paths. The performance of the algorithm is evaluated using both a sample of simulated Higgs boson events, in which the Higgs boson decays to long-lived neutral particles that in turn decay to bbar b final states, and pp collision data at √s = 7 TeV collected with the ATLAS detector at the LHC during 2011